Note: Lancet requires free registration prior to providing content. “Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study,” by W. David Strain, Valentina Lukashevich, Wolfgang Kothny, Marie-Jose Hoellinger, and Paivi Maria Paldanius (Vol. 382, No. 9890, August 3, 2013, p. 407-416).
www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60995-2/abstract
